Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
Breast Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Immunotherapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
The most common side effects of immunotherapy are rash, diarrhea, and fatigue, which is feeling exhausted or extremely tired. Learn more about the side effects of immunotherapy and steps you can take to manage or prevent them.
Sources: diarrhea · fatigue · side effects of immunotherapy
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Different types of treatments are available for inflammatory breast cancer. You and your cancer care team will work together to decide on your treatment plan, which likely will include more than one type of treatment. Learn more about inflammatory breast cancer symptoms, diagnosis, and prognosis at Inflammatory Breast Cancer.
Sources: Inflammatory Breast Cancer
Inflammatory breast cancer is always diagnosed as either stage III or stage IV disease. Learn more about how breast cancer is staged at Breast Cancer Stages.
Sources: Breast Cancer Stages
Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treating stage III (also called stage 3) inflammatory breast cancer
Stage III inflammatory breast cancer is generally treated with a combination of chemotherapy, surgery to remove the tumor, and radiation therapy. Immunotherapy, targeted therapy, and hormone therapy may also be given, depending on whether the cancer has certain biomarkers.
Sources: chemotherapy · radiation therapy · Immunotherapy · targeted therapy · hormone therapy · biomarkers
Chemotherapy. For stage III inflammatory breast cancer, chemotherapy is often used to help shrink the tumor before surgery to remove it. When chemotherapy is given before surgery, it is called neoadjuvant chemotherapy. Neoadjuvant chemotherapy may also reduce the number of lymph nodes that need to be removed during surgery. Chemotherapy may also be given after surgery (called adjuvant chemotherapy). Learn more about Chemotherapy for Breast Cancer.
Sources: lymph nodes · Chemotherapy for Breast Cancer
Surgery. The standard type of surgery for inflammatory breast cancer is a modified radical mastectomy, which removes the entire breast and the lymph nodes under the arm. Since inflammatory breast cancer affects large areas of skin on the breast, lumpectomy (breast-conserving surgery) and skin-sparing mastectomy are not options. Learn more about Mastectomy.
Sources: modified radical mastectomy · lumpectomy · Mastectomy
Radiation therapy. After surgery, you will likely have radiation therapy to the chest wall where the breast was removed to reduce the chance of breast cancer returning in the breast or chest wall. Learn more about Radiation for Breast Cancer.
Sources: chest wall · Radiation for Breast Cancer
Hormone therapy. You may receive hormone therapy if the cancer tests positive for estrogen receptors and/or progesterone receptors. Hormone therapy may also be given when the hormone receptor status of the cancer is unknown. Hormone therapy for inflammatory breast cancer is typically started during or after radiation therapy. Learn more about Hormone Therapy for Breast Cancer.
Sources: estrogen receptors · progesterone receptors · hormone receptor status · Hormone Therapy for Breast Cancer
Immunotherapy. You may receive immunotherapy, such as pembrolizumab, if biomarker tests suggest that the cancer is triple-negative. Learn more about Immunotherapy for Breast Cancer.
Sources: pembrolizumab · triple-negative · Immunotherapy for Breast Cancer
Targeted therapy. You may receive targeted therapy, such as trastuzumab, if biomarker tests suggest that the cancer has certain biomarkers. Learn more about Targeted Therapy for Breast Cancer.
Sources: trastuzumab · biomarkers · Targeted Therapy for Breast Cancer
Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treating metastatic or stage IV (also called stage 4) inflammatory breast cancer
In metastatic (stage IV or stage 4) inflammatory breast cancer, the cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. Treatment for stage IV inflammatory breast cancer is the same as treatment for other types of metastatic breast cancer.
Learn more about treatment options at Metastatic Breast Cancer in the section, “How is metastatic breast cancer treated?”
Sources: Metastatic Breast Cancer
Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treatment for recurrent inflammatory breast cancer
If cancer returns to the place where it began or nearby, it is called a locoregional recurrence. Treatment for locoregional recurrence of inflammatory breast cancer may include chemotherapy, surgery, and radiation. Other drugs may be added, depending on whether your cancer has certain biomarkers. Treatment for inflammatory breast cancer that has come back in distant parts of the body may be similar to treatment for stage IV breast cancer.
Sources: recurrence
Learn more about Breast Cancer Recurrence.
Sources: Breast Cancer Recurrence
Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Clinical trials
Connect with a cancer information specialist at 1-800-4-CANCER, through live chat, or by email.
Joining a clinical trial may be an option. There are different types of clinical trials for people with breast cancer. For example, a treatment trial tests new treatments or new ways of using existing treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials that are accepting participants. This search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. You can also review a list of NCI-supported Breast Cancer Clinical Trials. Clinical trials supported by other organizations can be found at ClinicalTrials.gov.
Sources: clinical trial search · Breast Cancer Clinical Trials · ClinicalTrials.gov
Learn more about clinical trials at Cancer Clinical Trial Information for Patients and Caregivers.
Sources: Cancer Clinical Trial Information for Patients and Caregivers
Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Coping with inflammatory breast cancer treatment
Treatment for inflammatory breast cancer can be mentally and physically challenging. It is important that you bring up any questions and concerns you have with your health care team throughout your care and treatment to get the support you need.
In addition to support from your health care team and family, one-on-one counseling or in-person and online support groups can help you cope and improve your mental wellbeing. Learn more about how to manage the physical and emotional effects of breast cancer at Living with Breast Cancer and Survivorship.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Radiation is given in a series of treatments to allow healthy cells to recover and to make radiation more effective. The number of treatments is based on details about the cancer, such as the size and location of the tumor. Most of the time, radiation is given as an outpatient treatment. This means that you will have treatment at a clinic or radiation therapy center and will not stay overnight in the hospital.
Sources: x-rays · radiation · outpatient
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Types of radiation therapy for breast cancer
External beam radiation therapy and brachytherapy (internal radiation therapy) are the main types of radiation therapy used for breast cancer. External beam radiation therapy comes from a machine that aims radiation at the cancer. For internal radiation therapy, the radiation source is placed inside the body near the cancer.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
External beam radiation therapy is a local treatment, which means it treats a specific part of your body. It may be given to the whole breast or chest, or to the part of the breast where the cancer is or where it was located before it was removed by surgery. Most of the time, you will get external beam radiation therapy as an outpatient.
To learn how to prepare for radiation therapy, visit the booklet Radiation Therapy and You: Support for People with Cancer.
Sources: Radiation Therapy and You: Support for People with Cancer
Radiation therapy for breast cancer usually begins about a month or two after surgery. That is because radiation therapy can slow wound healing. If you are also receiving chemotherapy, radiation therapy usually starts about a month after you have finished chemotherapy. You can have radiation at the same time as you are receiving some other treatments, such as hormone therapy or targeted therapy.
Sources: chemotherapy · hormone therapy · targeted therapy
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
With this type of radiation therapy, an x-ray machine delivers radiation to either the whole breast, or, if done after mastectomy, to the entire chest wall. Sometimes, radiation will also target the lymph nodes in the armpit or neck area or under the breastbone. Most people have treatment once a day, Monday through Friday, for about 5 to 6 weeks. In some cases, it may be done in 4 weeks or less. Your doctor will recommend the treatment regimen that is right for you.
Sources: mastectomy · chest wall · lymph nodes
This type of cancer treatment comes from a machine that aims radiation at a specifc part of your body.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Two techniques are commonly used to give external beam radiation treatment to the area where the cancer is or where it was located before it was removed by surgery:
Three-dimensional conformal external beam radiation (3DCRT) shapes the radiation beams to match the tumor’s shape, delivering a fixed dose of radiation from many directions.
Intensity-modulated radiation therapy (IMRT) also aims the radiation beams at the tumor from many directions. But IMRT also varies the intensity of radiation across the treatment area to allow higher doses of radiation to be given in areas needing more treatment and lower doses to be given in areas near sensitive organs or tissues.
Most people have treatment once a day, Monday through Friday, for 2 to 4 weeks.
Researchers are looking at other ways to adjust the radiation dose or schedule to reach the total dose of radiation more quickly or to limit damage to healthy cells.
Accelerated fractionation is treatment given in larger daily or weekly doses to reduce the number of weeks of treatment.
Sources: fractionation
Hyperfractionation is a smaller dose than the usual daily dose of radiation given more than once a day.
Sources: Hyperfractionation
Hypofractionation is larger doses given once a day or less often to reduce the number of treatments.
Sources: Hypofractionation
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Intraoperative radiation therapy is a type of external beam radiation therapy in which a single dose of radiation therapy is delivered to the tumor site during surgery.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Brachytherapy (also called internal radiation therapy) is sometimes used after breast-conserving surgery. It involves placing radioactive material using seeds, pellets, or needles in the area where the cancer was removed. The radiation only reaches a small area around the surgical site, where the risk of recurrence is highest.
Sources: breast-conserving surgery
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Intracavitary brachytherapy is the most common type of brachytherapy for breast cancer. In this form of brachytherapy, a balloon, applicator, or similar device is inserted into the space where the cancer was, either during or a few days after breast-conserving surgery. A radioactive pellet is placed into the device during each treatment session and then removed after each treatment.
Treatments usually last about 5 to 10 minutes and are given 2 times a day for 5 days. After about 2 weeks, the device is removed. You may need stitches to close the hole when treatment is complete.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
In interstitial brachytherapy, several small tubes, called catheters, are inserted into the tissue where the breast cancer was and stitched in place. This is most often done 1 to 2 weeks after surgery. A radiation source, such as radioactive pellets or seeds, is temporarily placed into the catheters during each treatment session. Treatments usually last about 20 minutes. Two kinds of sources, high-dose implants and low-dose implants, can be used:
High-dose implants: If you receive high-dose implants, the radiation is delivered once or twice a day for about 5 days. You will be able to leave the hospital after each treatment, and you will not remain radioactive after. It is safe to be around others, including babies and children.
Low-dose implants: If you receive low-dose implants, treatment can be delivered over several hours to days. The radiation source stays in place and is slowly delivered to the tissue around the catheters. You will stay in the hospital throughout treatment to avoid exposing others to radiation. The radiation source and catheters are removed when treatment is complete. Then you can go home.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
PBSI involves placing permanent radioactive seeds into the breast tissue around the area where the cancer was removed. The seeds emit radiation at a low dose. Although the seeds remain in the body, they lose their radioactivity over time and do not need to be removed. This is a one-time procedure that usually does not require a hospital stay.
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Intravenous radiation with strontium-89 (a radionuclide) is given as palliative therapy to relieve bone pain caused by breast cancer that has spread to the bones. Strontium-89 is injected into a vein and travels to the surface of the bones. Radiation is released and kills cancer cells in the bones.
Sources: radionuclide
Learn more about Brachytherapy to Treat Cancer.
Sources: Brachytherapy to Treat Cancer
Source: Radiation for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Side effects of radiation therapy for breast cancer
Radiation kills or slows the growth of cancer cells and can also affect nearby healthy cells. Damage to healthy cells can cause side effects. Your experience may be different from someone else who is getting the same amount of radiation therapy to the same part of the body. Sometimes, people may have side effects that do not improve.
Possible early side effects of radiation therapy for breast cancer include:
fatigue (feeling exhausted and worn out)
Sources: fatigue
hair loss in the area exposed to radiation
Sources: hair loss
skin changes, such as redness and dryness, in the area exposed to radiation
Sources: skin changes
breast tenderness or hardening
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects.
Possible late effects of radiation therapy for breast cancer include:
skin changes, such as redness and dryness, in the area exposed to radiation
breast pain, tenderness, or hardening
heart and lung problems
bone weakness
lymphedema
Sources: lymphedema
second cancers, rarely
Learn more about Late Effects of Cancer Treatment.
Sources: Late Effects of Cancer Treatment
Discuss potential side effects with your doctor or nurse so you know what to expect during and after treatment. Regular follow-up care and supportive care can help manage side effects that do occur.
Learn more about Living with Breast Cancer and Survivorship.
Source: Breast Cancer Surgery, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Most people with breast cancer or ductal carcinoma in situ (DCIS) will have surgery to remove the tumor and nearby breast tissue. The two main types of surgery are lumpectomy (breast-conserving surgery) and mastectomy, with or without breast reconstruction.
Sources: ductal carcinoma in situ · tissue · lumpectomy · mastectomy · breast reconstruction
Breast cancer surgery may also involve checking nearby lymph nodes for cancer. Usually, a sentinel lymph node biopsy is done, often during a lumpectomy or mastectomy but sometimes as a separate surgery. Learn more about sentinel lymph node biopsy at How Breast Cancer Is Diagnosed.
Sources: lymph nodes · sentinel lymph node biopsy · How Breast Cancer Is Diagnosed
Source: Breast Cancer Surgery, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Lumpectomy (Breast-Conserving Surgery) Learn about lumpectomy, additional treatments you may need, your options for reconstruction, and lumpectomy risks.
Mastectomy Learn about different types of mastectomies, additional treatments you may need, your options for reconstruction, and mastectomy risks.
Lumpectomy vs. Mastectomy Get answers to common questions about lumpectomy and mastectomy that can help you choose an option that is right for you.
Breast Reconstruction After Mastectomy Learn about your options for breast reconstruction, including types of reconstruction and factors that may affect your choice.
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
What is breast reconstruction?
Many women who have a mastectomy—surgery to remove an entire breast to treat or prevent breast cancer—have the option of having the shape of the removed breast rebuilt. Some people choose not to have their breasts reconstructed after a mastectomy, instead preferring a flat closure.
Sources: flat closure
Breasts can be rebuilt using implants (saline or silicone) or autologous tissue (that is, tissue from elsewhere in the body). Sometimes both implants and autologous tissue are used to rebuild the breast.
Sources: saline · silicone · autologous
Surgery to reconstruct the breasts can be done (or started) at the time of the mastectomy, called immediate reconstruction, or it can be done after the mastectomy incisions have healed and treatment has been completed, called delayed reconstruction. Delayed reconstruction can happen months or even years after the mastectomy.
In the final stage of breast reconstruction, a nipple and areola may be re-created on the reconstructed breast, if these were not preserved during the mastectomy.
Sometimes breast reconstruction surgery includes surgery on the other, or contralateral, breast so that the two breasts will match in size and shape.
Sources: contralateral
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
How do surgeons use implants to reconstruct a woman's breast?
Implants are inserted underneath the skin or chest muscle following the mastectomy. Implants are usually placed as part of a two-stage procedure.
In the first stage, the surgeon places a device called a tissue expander under the skin that is left after the mastectomy or under the chest muscle (1, 2). The expander is slowly filled with saline or air during periodic visits to the doctor after surgery.
In the second stage, after the chest tissue has relaxed and healed enough, the expander is removed and replaced with an implant. The chest tissue is usually ready for the implant 2 to 6 months after the tissue expander is placed.
In some cases, the implant can be placed in the breast during the same surgery as the mastectomy—that is, a tissue expander is not used (3).
Sources: 3
Surgeons are increasingly using material called acellular dermal matrix as a kind of scaffold or “sling” to support tissue expanders and implants. Acellular dermal matrix is a kind of mesh that is made from donated human or pig skin that has been sterilized and processed to remove all cells to eliminate the risks of rejection and infection.
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
How do surgeons use tissue from a woman's own body to reconstruct the breast?
In autologous tissue reconstruction, a piece of tissue containing skin, fat, blood vessels, and sometimes muscle is taken from elsewhere in a woman’s body and used to rebuild the breast. This piece of tissue is called a flap.
Sources: autologous
Different sites in the body can provide flaps for breast reconstruction. Flaps most often come from the abdomen or back. However, they can also be taken from the thigh or buttocks.
Sources: abdomen
Depending on their source, flaps can be pedicled or free.
With a pedicled flap, the tissue and attached blood vessels are moved together through the body to the breast area. Because the blood supply to the tissue used for reconstruction is left intact, blood vessels do not need to be reconnected once the tissue is moved.
Sources: pedicled flap
With free flaps, the tissue is cut free from its blood supply. It must be attached to new blood vessels in the breast area, using a technique called microsurgery, to give the reconstructed breast a blood supply.
Sources: free flaps
Abdominal and back flaps include:
DIEP flap: Tissue comes from the abdomen and contains only skin, blood vessels, and fat, without the underlying muscle. This type of flap is a free flap.
Latissimus dorsi (LD) flap: Tissue comes from the middle and side of the back. This type of flap is pedicled when used for breast reconstruction. (LD flaps can also be used for other types of reconstruction, such as abdominal or head and neck reconstruction.)
SIEA flap (also called SIEP flap): Tissue comes from the abdomen as in a DIEP flap but includes a different set of blood vessels. It also does not involve cutting of the abdominal muscle and is a free flap. This type of flap is not usually an option for breast reconstruction because the necessary blood vessels are often not adequate or do not exist.
TRAM flap: Tissue comes from the lower abdomen as in a DIEP flap but includes muscle. TRAM flaps can be either pedicled or free.
Sources: TRAM flap
Flaps taken from the thigh or buttocks are used for women who have had previous major abdominal surgery or who don’t have enough abdominal tissue to reconstruct a breast. These types of flaps are free flaps.
IGAP flap: Tissue comes from the buttocks and contains only skin, blood vessels, and fat.
PAP flap: Tissue, without muscle, comes from the upper inner thigh.
SGAP flap: Tissue comes from the buttocks as in an IGAP flap but includes a different set of blood vessels and contains only skin, blood vessels, and fat.
TUG flap: Tissue, including muscle, comes from the upper inner thigh.
The table below summarizes the different types of flaps used for breast reconstruction:
| Name of flap | Type of flap | Source of tissue | Includes muscle? |
|---|---|---|---|
| DIEP | Free | Abdomen | No |
| Latissumus dorsi | Pedicled | Middle and side of back | Yes |
| SIEA/SIEP | Free | Abdomen | No |
| TRAM | Pedicled or free | Lower abdomen | Yes |
| IGAP | Free | Buttocks | No |
| PAP | Free | Upper inner thigh | No |
| SGAP | Free | Buttocks | No |
| TUG | Free | Upper inner thigh | Yes |
In some cases, an implant and autologous tissue are used together. For example, with flaps taken from the thigh or buttocks an implant is often used as well to provide sufficient breast volume. Also, autologous tissue may be used to cover an implant when there isn’t enough skin and muscle left after mastectomy to allow for expansion and use of an implant (1, 2).
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
How do surgeons reconstruct the nipple and areola?
After the chest heals from reconstruction surgery and the position of the breast mound on the chest wall has had time to stabilize, the nipple and areola can be reconstructed. This can be done in two ways—surgically or with tattoos.
Sources: chest wall · nipple · areola
For surgical nipple reconstruction, the new nipple is created by cutting and moving small pieces of skin from the reconstructed breast to the nipple site and shaping them into a new nipple. A few months later, the surgeon can re-create the areola. This is usually done using tattoo ink.
However, in some cases, skin grafts may be taken from the groin or abdomen and attached to the breast to create an areola at the time of the nipple reconstruction (1).
Sources: skin grafts · 1
Alternatively, a new nipple and areola can be created by a tattoo artist who specializes in 3-D nipple tattooing. Such a nipple is flat to the touch but looks realistic.
Sources: 3-D
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
What factors can affect the timing of breast reconstruction?
One factor that can affect the timing of breast reconstruction is whether a woman will need radiation therapy. Radiation therapy can sometimes cause wound healing problems or infections in reconstructed breasts, so some women may prefer to delay reconstruction until after radiation therapy is completed. However, because of improvements in surgical and radiation techniques, immediate reconstruction with an implant is usually still an option for women who will need radiation therapy. Autologous tissue breast reconstruction is usually reserved for after radiation therapy, so that the breast and chest wall tissue damaged by radiation can be replaced with healthy tissue from elsewhere in the body.
Sources: radiation therapy · Autologous · chest wall
Even if a woman is a candidate for immediate reconstruction, she may choose delayed reconstruction. For instance, some women prefer not to consider what type of reconstruction to have until after they have recovered from their mastectomy and subsequent adjuvant treatment. Women who delay reconstruction (or choose not to undergo the procedure at all) can use external breast prostheses, or breast forms, to give the appearance of breasts.
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
What factors can affect the choice of breast reconstruction method?
Several factors can influence the type of reconstructive surgery a woman chooses. These include the size and shape of the breast that is being rebuilt, the woman’s age and health, her history of past surgeries, her risk factors for complications after surgery (for example, smoking history and obesity), the availability of autologous tissue, and the location of the tumor in the breast (2, 6). Women who have had past abdominal surgery may not be candidates for an abdominally based flap reconstruction.
Sources: reconstructive surgery · risk factors · complications · autologous · 2 · 6
Each type of reconstruction has factors that a woman should think about before making a decision. Some of the more common considerations are listed below.
Reconstruction with Implants
Surgery and recovery
Enough skin and muscle must remain after mastectomy to cover the implant
Shorter surgical procedure than for reconstruction with autologous tissue; little blood loss
Recovery period may be shorter than with autologous reconstruction
Many follow-up visits may be needed to inflate the expander and insert the implant
Possible complications
Infection
Accumulation of clear fluid causing a mass or lump (seroma) within the reconstructed breast (7)
Pooling of blood (hematoma) within the reconstructed breast
Sources: hematoma
Blood clots
Sources: Blood clots
Extrusion of the implant (the implant breaks through the skin)
Implant rupture (the implant breaks open and saline or silicone leaks into the surrounding tissue)
Formation of hard scar tissue around the implant (known as a contracture)
Sources: contracture
Obesity, diabetes, and smoking may increase the rate of complications
Sources: diabetes
Very small risk of developing a very rare form of immune system cancer called breast implant associated–anaplastic large cell lymphoma, particularly with textured implants
Sources: breast implant associated–anaplastic large cell lymphoma
A small number of squamous cell carcinomas and various lymphomas in the scar tissue around implants have been reported, but they are very rare
Other considerations
May not be an option for patients who have previously undergone radiation therapy to the chest
Sources: radiation therapy
May not be adequate for women with very large breasts
Will not last a lifetime; the longer a woman has implants, the more likely she is to have complications and to need to have her implants removed or replaced
Silicone implants may feel more natural than saline implants to the touch
The Food and Drug Administration (FDA) recommends that women with silicone implants undergo periodic MRI screenings to detect possible “silent” rupture of the implants
Sources: MRI
More information about implants can be found on FDA’s Breast Implants page.
Sources: Breast Implants
Reconstruction with Autologous Tissue
Surgery and recovery
Longer surgical procedure than for implants
The initial recovery period may be longer than for implants
Pedicle flap reconstruction is usually a shorter operation than free flap reconstruction and usually requires a shorter hospitalization
Sources: free flap
Free flap reconstruction is a highly technical operation that requires a surgeon who has experience with microsurgery to reattach blood vessels.
Possible complications
Necrosis (death) of the transferred tissue
Sources: Necrosis
The risk of bleeding and blood clots is higher with autologous reconstruction than with implants
Pain and weakness at the site from which the donor tissue was taken
Obesity, diabetes, and smoking may increase the rate of complications
Other considerations
May provide a more natural breast shape than implants
May feel softer and more natural to the touch than implants
Leaves a scar at the site from which the donor tissue was taken
Can be used to replace tissue that has been damaged by radiation therapy
Sources: radiation therapy
All women who undergo mastectomy for breast cancer experience varying degrees of numbness and loss of feeling in the breast because nerves that provide sensation to the breast are cut when breast tissue is removed during surgery. However, some breast sensation may be regained as the severed nerves grow and regenerate, and breast surgeons continue to make technical advances that can spare or repair damage to nerves.
Any type of breast reconstruction can fail if healing does not occur properly. In these cases, the implant or flap will have to be removed. If an implant reconstruction fails, a woman can usually have a second reconstruction using an alternative approach.
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Will health insurance pay for breast reconstruction?
The Women’s Health and Cancer Rights Act of 1998 (WHCRA) is a federal law that requires group health plans and health insurance companies that offer mastectomy coverage to also pay for reconstructive surgery after mastectomy. This coverage must include all stages of reconstruction and surgery to achieve symmetry between the breasts, breast prostheses, and treatment of complications that result from the mastectomy, including lymphedema. More information about WHCRA is available from the Department of Labor and the Centers for Medicare & Medicaid Services.
Sources: reconstructive surgery · complications · lymphedema · Department of Labor · Centers for Medicare & Medicaid Services
Some health plans sponsored by religious organizations and some government health plans may be exempt from WHCRA. Also, WHCRA does not apply to Medicare or Medicaid. However, Medicare may cover breast reconstruction surgery as well as external breast prostheses (including a post-surgical bra) after a medically necessary mastectomy. Medicaid benefits vary by state; a woman should contact her state Medicaid office for information on whether, and to what extent, breast reconstruction is covered.
Sources: Medicare
A woman considering breast reconstruction may want to discuss costs and health insurance coverage with her doctor and insurance company before choosing to have the surgery. Some insurance companies require a second opinion before they will agree to pay for a surgery.
Sources: second opinion
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
What type of follow-up care and rehabilitation is needed after breast reconstruction?
Any type of reconstruction increases the number of side effects a woman may experience compared with those after a mastectomy alone. A woman’s medical team will watch her closely for complications, some of which can occur months or even years after surgery (1, 2, 8).
Sources: side effects · complications · 1 · 2 · 8
Women who have breast reconstruction may benefit from physical therapy to improve or maintain shoulder range of motion or help recover from weakness experienced at the site from which donor tissue was taken for an autologous reconstruction (9, 10). A physical therapist can help a woman use exercises to regain strength, adjust to new physical limitations, and figure out the safest ways to perform everyday activities.
Sources: physical therapy · 9 · 10 · physical therapist
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Does breast reconstruction affect the ability to check for breast cancer?
Mammography is not typically done on a breast that is reconstructed after mastectomy; instead, physical exams are done to check for recurrence. However, women who have one breast removed by mastectomy will still have mammograms of the other breast.
Sources: Mammography · physical exams · recurrence
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
What is flat closure?
A flat closure (also called aesthetic flat closure) is surgery done to rebuild the shape of the chest wall after the removal of one or both breasts. It is also a surgical option for people who have had their breast implants removed.
Sources: aesthetic flat closure · chest wall
During an aesthetic flat closure, a surgeon removes extra skin, fat, and other tissue in the breast area. The remaining tissue is then tightened and smoothed out so that the chest wall appears flat and contoured. Simply forgoing additional procedures to reconstruct the breast(s) after a mastectomy will not achieve a flat closure (11).
Sources: 11
Source: Breast Reconstruction After Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
What are some new developments in breast reconstruction after mastectomy?
Oncoplastic surgery. In general, women who have lumpectomy or partial mastectomy for early-stage breast cancer do not have reconstruction. However, in some cases the surgeon may use plastic surgery techniques to reshape the breast at the time of cancer surgery. This type of breast-conserving surgery, called oncoplastic surgery, may use local tissue rearrangement, reconstruction through breast reduction surgery, or transfer of tissue flaps. Long-term outcomes of this type of surgery are comparable to those for standard breast-conserving surgery (12).
Sources: lumpectomy · partial mastectomy · early-stage breast cancer · plastic surgery · breast-conserving surgery · 12
Autologous fat grafting. A newer type of breast reconstruction technique involves the transfer of fat tissue from one part of the body (usually the thighs, abdomen, or buttocks) to the reconstructed breast. The fat tissue is harvested by liposuction, washed, and liquified so that it can be injected into the area of interest. Fat grafting is mainly used to correct deformities and asymmetries that may appear after breast reconstruction. It is also sometimes used to reconstruct an entire breast. Although concern has been raised about the lack of long-term outcome studies, this technique is considered safe (1, 6, 13).
Sources: liposuction · 1 · 6 · 13
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Are you facing a decision about lumpectomy vs. mastectomy?
Do you have ductal carcinoma in situ (DCIS) or breast cancer that can be removed with surgery? If so, you may be able to choose which type of breast surgery you have. Often, your choice is between a lumpectomy or other breast-conserving surgery (surgery that takes out the cancer and leaves most of the breast) and a mastectomy (surgery that removes the whole breast).
Sources: ductal carcinoma in situ · lumpectomy · mastectomy
Learn more about these surgeries at Breast Cancer Surgery.
Sources: Breast Cancer Surgery
Once you are diagnosed, treatment will usually not begin right away. Use the time to:
talk with your doctor
get a second opinion
check with your insurance company
learn the facts about your surgery choices
think about what is important to you
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Compare lumpectomy and mastectomy
If your surgeon gives you a choice about which surgery to have, it can be hard to decide which one is best for you. This section can help you compare the different surgeries. Learn how the surgeries are alike and how they are different by clicking on each question to learn more.
Which type of breast cancer surgery is best for my cancer?
Sources: Which type of breast cancer surgery is best for my cancer?
Will the type of surgery I have affect how long I live?
Sources: Will the type of surgery I have affect how long I live?
What are the chances that my breast cancer will return in the same area?
Sources: What are the chances that my breast cancer will return in the same area?
Will I have pain?
Sources: Will I have pain?
How long before I can return to normal activities?
What other problems might I have from the surgery?
What other types of treatment might I need?
Will I need more surgery?
Sources: Will I need more surgery?
What will my breast look like after surgery?
Will my breast have feeling after surgery?
Will the type of surgery I choose affect my quality of life?
Sources: Will the type of surgery I choose affect my quality of life?
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | Most women with DCIS or breast cancer can choose to have a lumpectomy (breast-conserving surgery), usually followed by radiation therapy. |
|---|---|
| Mastectomy | Most women with DCIS or breast cancer can choose to have a mastectomy. A mastectomy may be a better choice for you if:you have small breasts and a large area of DCIS or canceryou have DCIS or cancer in more than one part of your breastthe DCIS or cancer is under the nippleyou are not able or prefer not to receive radiation therapy |
| Mastectomy with reconstruction | If you have a mastectomy, you might also want breast reconstruction surgery. You can choose to have reconstruction surgery at the same time as your mastectomy or wait and have it later. Your surgeon can talk with you about how much skin, including the nipple and areola, might be preserved for reconstruction. |
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
No. Research shows that women who have breast-conserving surgery live as long as women who have a mastectomy. This does not change if you also have reconstruction.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | There is a chance that your cancer will come back in the same breast if you have a lumpectomy. But if it does, it is not likely to affect how long you live. About 5% to 10% of women (1 out of every 10 to 20) who have a lumpectomy followed by radiation therapy get cancer in the same breast within 12 years. If this happens, you can be effectively treated with a mastectomy. |
|---|---|
| Mastectomy | There is a chance that your cancer will return in the same breast that was removed. This is called a local recurrence. It can happen after a mastectomy because surgeons cannot remove every bit of breast tissue. Also, the cancer can come back in the chest muscle or chest wall.Local recurrence is slightly less likely after mastectomy than after lumpectomy. About 1 out of every 20 women who have a mastectomy will get cancer on the same side of their chest within 12 years. |
| Mastectomy with reconstruction | Your chances are the same as mastectomy because breast reconstruction surgery does not affect the chances of the cancer returning. |
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Most people have some pain after surgery. Talk with your doctor or nurse before surgery about ways to control pain after surgery. Also, tell them if your pain control is not working.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | Most women are ready to return to most of their usual activities within 2 weeks. |
|---|---|
| Mastectomy | It may take 3 to 4 weeks to feel mostly normal after a mastectomy. |
| Mastectomy with reconstruction | Your recovery will depend on the type of reconstruction you have. It can take 6 to 8 weeks or longer to fully recover from a mastectomy that is followed by breast reconstruction. |
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | You may feel very tired and have skin changes from radiation therapy. |
|---|---|
| Mastectomy | You may feel out of balance if you had large breasts and do not have reconstruction surgery. This may also lead to neck and shoulder pain. |
| Mastectomy with reconstruction | You may not like how your breast-like shape looks. If you have an implant, your breast may harden and can become painful. If your implant breaks or leaks you may need more surgery. If you have tissue flap reconstruction, you may lose strength in the part of your body where a muscle was removed. |
Sources: tissue flap reconstruction
If lymph nodes are removed from under your arm, you may develop lymphedema. Learn more about Lymphedema.
Sources: lymph nodes · Lymphedema
Learn about local and systemic treatments and access in-depth information about each type of treatment.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
If you choose to have a lumpectomy or other breast-conserving surgery, you will usually need radiation therapy. Radiation treatments are often given 5 days a week for up to 6 weeks.
Sources: radiation therapy
If you have a mastectomy, you may still need radiation therapy.
No matter which surgery you choose, you might need:
chemotherapy
Sources: chemotherapy
hormone therapy
Sources: hormone therapy
targeted therapy
Sources: targeted therapy
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | After surgery, if there are cancer cells at the edge of the removed breast tissue, then you may need more surgery to make sure that all the cancer is removed. |
|---|---|
| Mastectomy | If you have problems after your mastectomy, you may need more surgery. |
| Mastectomy with reconstruction | You will most likely need more than one surgery to build a new breast-like shape. The number of surgeries you need will depend on the type of reconstruction you have and if you choose to have a nipple or areola added.Some women may also decide to have surgery on the opposite breast to help it better match the reconstructed breast.If you have an implant, you are likely to need surgery many years later to remove or replace it. |
With all three surgeries, you may need more surgery to remove lymph nodes from under your arm to see how far the cancer has spread.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | Your breast should look a lot like it did before surgery.But if your tumor is large, your breast may look different or smaller after breast-conserving surgery.You will have a small scar where the surgeon cut to remove the DCIS or cancer. The length of the scar will depend on how large the incision was. |
|---|---|
| Mastectomy | If you have a mastectomy without reconstruction, your breast and nipple will be removed. You will have a flat chest on the side of your body where the breast was removed.You will have a scar over the place where your breast was removed. The length of the scar will depend on the size of your breast. The scar is usually shorter for smaller breasts and longer for larger breasts. |
| Mastectomy with reconstruction | If you have a skin- or nipple-sparing mastectomy, your skin and nipple will remain after surgery. You will not have the sensation of temperature or touch, but your nipple will still react to these.Even if you have reconstruction, your breast shape will not look or feel like it did before surgery. And it will not look or feel like your other breast. You will have scars where the surgeon stitched skin together to make the new breast-like shape. If you have tissue flap reconstruction, you will have scars around the new breast, as well as in the area where the surgeon removed the muscle, fat, and skin to make the new breast-like shape. |
With all three surgeries, the scars left from where the surgeon cut the skin and stitched it back together tend to fade over time.
To get a better idea of what to expect from surgery, ask your surgeon if you can see before and after pictures of other people who have had different types of surgery.
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
| Lumpectomy or other breast-conserving surgery | Yes. You should still have feeling in your breast, nipple, and areola. |
|---|---|
| Mastectomy | Maybe. After surgery, the skin around where the surgeon cut and maybe the area under your arm will be numb. This numb feeling may improve over 1 to 2 years, but it will never feel like it once did. Also, the skin where your breast was may feel tight. |
| Mastectomy with reconstruction | No. Most of the area around your breast will not have feeling. |
Some surgeons are trying new techniques to preserve or restore breast feeling after a mastectomy. Find clinical trials studying this issue using our NCI-supported clinical trials search or ClinicalTrials.gov.
Sources: clinical trials search · ClinicalTrials.gov
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Research suggests that women who have breast-conserving surgery have a better long-term quality of life than those who have a mastectomy.
Sources: have a better long-term quality of life than those who have a mastectomy
Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Think about what is important to you
After you have talked with a breast surgeon and learned the facts, you may also want to talk with your spouse or partner, family, friends, or other women who have had breast cancer surgery.
Then, think about what is important to you. Thinking about the following questions and talking them over with others might help:
If I have a lumpectomy or other breast-conserving surgery, am I willing and able to have radiation therapy 5 days a week for up to 6 weeks?
If I have a lumpectomy and the cancer comes back later in the same breast, how would I feel about needing a mastectomy?
If I have a mastectomy, do I also want breast reconstruction surgery?
If I have breast reconstruction surgery, do I want it at the same time as the mastectomy?
What treatment does my insurance cover? What do I have to pay for?
How important is it to me how my breast looks after cancer surgery?
How important is it to me how my breast feels after cancer surgery?
If I have a mastectomy and do not have reconstruction, will my insurance cover prostheses and special bras?
Where can I find breast prostheses and special bras?
Do I want a second opinion?
Is there someone else I should talk with about my surgery choices?
What else do I want to learn or do before I decide about breast cancer surgery?
Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Lumpectomy is a type of breast surgery in which the surgeon removes the ductal carcinoma in situ (DCIS) or breast cancer and some healthy tissue around it. If the cancer is near the chest wall, part of the chest wall lining may also be removed.
Sources: ductal carcinoma in situ · breast cancer · tissue · chest wall
Lumpectomy is an option for some people with DCIS or invasive breast cancer. It is usually followed by radiation therapy. Research shows that lumpectomy plus radiation therapy is just as effective as mastectomy (surgery to remove all breast tissue) at lowering your chance of dying from breast cancer or of the cancer coming back. Learn more about choosing between a mastectomy and lumpectomy to treat breast cancer.
Sources: radiation therapy · mastectomy · Learn more about choosing between a mastectomy and lumpectomy to treat breast cancer.
Your doctor may suggest a lumpectomy plus radiation therapy if:
the cancer or DCIS is small relative to the size of the breast
the cancer or DCIS is found in only one place in the breast
you are not pregnant and are able to have daily radiation therapy for up to 6 weeks
If large amounts of tissue need to be removed during a lumpectomy, the surgery may be called partial mastectomy, segmental mastectomy, or quadrantectomy.
After a lumpectomy, a pathologist will check the healthy tissue that was removed to see if it contains DCIS or cancer. If it does, you may need more surgery or a mastectomy so the surgeon can remove more tissue and make sure no DCIS or cancer cells remain in the breast.
Sources: pathologist
Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Most people who have a lumpectomy receive radiation therapy after they heal from surgery. The goal of this treatment is to keep cancer from coming back in the same breast. Learn more about Radiation for Breast Cancer.
Sources: Radiation for Breast Cancer
You might also need chemotherapy, hormone therapy, or targeted therapy, before or after surgery. Learn more about Breast Cancer Treatment.
Sources: chemotherapy · hormone therapy · targeted therapy · Breast Cancer Treatment
The type of treatment you receive will depend on many factors, such as how different the tumor cells look from normal breast cells, how likely the tumor cells are to grow and spread, and the results of biomarker tests. Learn more at How Breast Cancer Is Diagnosed and Tests for Breast Cancer Biomarkers.
Sources: cells · biomarker · How Breast Cancer Is Diagnosed · Tests for Breast Cancer Biomarkers
Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Most people can go home the day of their lumpectomy and go about their daily activities with few restrictions. But you may need help with some tasks, depending on the extent of your surgery. Within two weeks, you should be able to return to your normal activities.
Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
After a lumpectomy, your breast will usually look and feel much like it did before surgery. You will have a scar at the site of surgery. And there may be a dent where the tumor and tissue were removed.
Talk to your surgical team about how your surgery might change how your breast looks. If you think you will not be happy with the look or feel of your breast after surgery, you may think about reconstruction. Reconstruction can take place during or any time after the lumpectomy.
There are two types of breast reconstruction for people who have a lumpectomy:
Oncoplastic surgery combines lumpectomy with plastic surgery that can help make the breasts look more even if large amounts of tissue are removed from one breast. It can also reduce scarring and dents. A plastic surgeon will often do this reconstruction during the same surgery as the lumpectomy.
Sources: plastic surgery
Revision reconstruction usually happens after you have healed from a lumpectomy. A plastic surgeon may be able to improve scarring and hardening of tissue at the surgical site. And they may be able to restore the shape of the breast with fat grafting, tissue flaps, or implants.
Sources: grafting · tissue flaps · implants
Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
As with any surgery, lumpectomy has risks, including:
bleeding and pain at the site of surgery
infection
Sources: infection
fluid buildup near the site of surgery
lymphedema, if lymph nodes are removed
Sources: lymphedema
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
In a mastectomy, the surgeon removes the whole breast that contains ductal carcinoma in situ (DCIS) or cancer. Your doctor may suggest a mastectomy if:
Sources: ductal carcinoma in situ
you have inflammatory breast cancer
Sources: inflammatory breast cancer
your breast has more than one tumor
you received radiation therapy to the chest in the past
Sources: radiation therapy
the cancer or DCIS is large relative to the size of the breast
you had a lumpectomy (breast-conserving surgery) that did not remove all the cancer cells
Sources: lumpectomy
you are at a high risk of a second breast cancer because of a genetic mutation or strong family history
Sources: genetic mutation
If you have a mastectomy, you may not need radiation therapy, so your doctor may also suggest a mastectomy if you are not able to have radiation therapy because you are pregnant or can’t commit to daily treatments.
People who have a mastectomy may need chemotherapy, hormone therapy, or targeted therapy. Learn more about Breast Cancer Treatment.
Sources: chemotherapy · hormone therapy · targeted therapy · Breast Cancer Treatment
After a mastectomy, you may choose to stay flat, wear a prosthesis (breast-like form) in your bra, or have breast reconstruction surgery.
Sources: breast reconstruction
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Types of mastectomy
Total mastectomy (also called simple mastectomy). In this type of surgery, the surgeon removes your whole breast, including the nipple, areola, breast tissue, and skin. Sometimes, they also remove one or more of the lymph nodes under your arm in a procedure called sentinel lymph node biopsy.
Sources: areola · tissue · lymph nodes · sentinel lymph node biopsy
Modified radical mastectomy. This is the same as a total mastectomy, but the surgeon also removes lymph nodes under your arm (axillary lymph node dissection). Because cancer cells may spread to the lymph nodes, lymph node removal can help reduce the risk of the cancer coming back. But it is often used only for more advanced stages of breast cancer.
Sources: axillary lymph node dissection
Skin-sparing mastectomy. The surgeon removes the whole breast, as in a total mastectomy, but leaves the skin. A skin-sparing mastectomy leaves less scarring and makes for a more natural-looking reconstructed breast. But if the tumor is large or near the skin, this procedure may not be an option. Skin-sparing mastectomies require breast reconstruction right after surgery.
Nipple-sparing mastectomy. The surgeon removes the whole breast but leaves the skin, nipple, and areola. Nipple-sparing mastectomy may not be an option if the tumor is large or if cancer cells are found near the skin, nipple, or areola. It also may not be an option for people with larger breasts.
Radical mastectomy. This type of mastectomy was common in the past, but it is now rarely performed because it does not improve how long people live. It involves removing the chest wall muscles and all lymph nodes, as well as the whole breast, nipple, areola, and skin. A surgeon may still suggest a radical mastectomy if the cancer cells have spread to the chest wall muscles.
Sources: chest wall
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Single vs. double mastectomy
In a single (unilateral) mastectomy, only the breast with cancer is removed. A double (bilateral) mastectomy involves the removal of both breasts.
Your doctor may suggest a double mastectomy if:
cancer is in both breasts
you have cancer in one breast but are at high risk of developing cancer in the other breast because of a genetic mutation or strong family history of breast cancer
If you do not have a genetic mutation or strong family history of breast cancer, you do not have an increased risk of developing a new cancer in the other breast. For you, research shows that having a double mastectomy instead of a single mastectomy does not help you live longer.
You may choose to have a double mastectomy, even if your doctor suggests a single mastectomy, if:
you want to reduce the risk of developing a new breast cancer in the healthy breast
you prefer not to have routine screening to check for cancer in the healthy breast
you want both breasts to be the same size
you are concerned about how your chest will look after a single mastectomy
Discuss insurance coverage and the risks and benefits of a double mastectomy with your doctor before making a decision.
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Mastectomy with breast reconstruction surgery
You can have breast reconstruction at the same time as the mastectomy, or at any time after. Some types of mastectomies (skin- and nipple-sparing) require reconstruction at the same time. Breast reconstruction is done by a plastic surgeon with experience in this type of surgery. The surgeon uses an implant or tissue from another part of your body to create the breast mound after the breast has been removed. If your nipple is removed, the surgeon may also make the form of a nipple and add a tattoo that looks like the areola.
Sources: plastic surgeon
For more information about types of breast reconstruction, recovery times, and possible complications, visit Breast Reconstruction After Mastectomy.
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Going flat after a mastectomy
You may choose to not have breast reconstruction after a mastectomy. This is called “going flat.” If you decide against reconstruction, you have the option of wearing a breast prosthesis to create the breast form under your clothes. To make the chest flat and smooth after a mastectomy, the surgeon will perform an aesthetic flat closure.
Sources: aesthetic flat closure
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Recovering after a mastectomy
Recovery after a mastectomy depends on the type of mastectomy you had and whether you had breast reconstruction. Most people begin returning to normal activities 4 weeks after surgery. But recovery could take longer for people who have breast reconstruction.
Source: Mastectomy, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Mastectomy risks
As with any surgery, a mastectomy has possible risks:
infection
pain or other discomfort that may or may not get better over time (postmastectomy pain syndrome and phantom breast syndrome)
arm and shoulder pain and stiffness
lymphedema in the arm, especially when many lymph nodes have been removed
Sources: lymphedema
Mastectomy with reconstruction has additional risks. Learn more at Breast Reconstruction After Mastectomy.
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Targeted therapy is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. To learn what to expect when receiving targeted therapy, visit Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Who gets targeted therapy for breast cancer?
Many people with breast cancer get targeted therapy but not everyone. For example, targeted therapy may be an option for some people with:
HER2-positive breast cancer
Sources: HER2-positive
hormone receptor–positive breast cancer
Sources: hormone receptor–positive
triple-negative breast cancer
Sources: triple-negative breast cancer
breast cancer that has a BRCA1 or BRCA2 mutation
Once breast cancer is diagnosed, breast cancer cells are routinely tested for the presence of certain biomarkers or tumor features. These tests can help determine if you are likely to benefit from targeted cancer therapy. To learn more, visit Tests for Breast Cancer Biomarkers.
Sources: biomarkers · Tests for Breast Cancer Biomarkers
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
When is targeted therapy for breast cancer given?
Targeted therapy for breast cancer may be given at different times in your treatment. It might be started before or after surgery. It can also be given even if surgery is not recommended for you.
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Targeted therapy for HER2-positive breast cancer
HER2 is a protein that helps control breast cell growth. Some breast cancers have too much HER2, which causes the breast cells to grow and divide faster than normal. This is called HER2-positive breast cancer.
Several targeted therapy drugs may be used alone or with other kinds of drugs for HER2-positive breast cancer:
lapatinib
Sources: lapatinib
margetuximab
Sources: margetuximab
neratinib
Sources: neratinib
pertuzumab
Sources: pertuzumab
pertuzumab, trastuzumab, and hyaluronidase-zzxf
tucatinib
Sources: tucatinib
trastuzumab
Sources: trastuzumab
trastuzumab and hyaluronidase-oysk
Sources: trastuzumab and hyaluronidase-oysk
trastuzumab deruxtecan
Sources: trastuzumab deruxtecan
Some of these targeted therapy drugs, such as trastuzumab and trastuzumab deruxtecan, may also be used for HER-low breast cancer. HER2-low breast cancers have a small amount of HER2 protein on their surface.
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Targeted therapy for hormone receptor–positive breast cancer
In hormone receptor–positive (HR positive) breast cancer, the breast cancer cells have estrogen or progesterone receptors, or both.
The following targeted therapy drugs may be used alone or with other treatments, particularly hormone therapy:
abemaciclib
Sources: abemaciclib
alpelisib
Sources: alpelisib
everolimus
Sources: everolimus
palbociclib
Sources: palbociclib
ribociclib
Sources: ribociclib
sacituzumab govitecan
Sources: sacituzumab govitecan
These drugs may be given with hormone therapy, such as an aromatase inhibitor (such as anastrozole, letrozole, or exemestane) or fulvestrant or letrozole, to treat hormone receptor–positive, HER2-negative breast cancer. Learn more about Hormone Therapy for Breast Cancer.
Sources: anastrozole · letrozole · exemestane · fulvestrant · letrozole · Hormone Therapy for Breast Cancer
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Targeted therapy for triple-negative breast cancer
Triple-negative breast cancer is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER2 negative.
The targeted therapy drug sacituzumab govitecan may be used to treat triple-negative breast cancer.
Sources: sacituzumab govitecan
Learn more about Triple-Negative Breast Cancer Treatment.
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Targeted therapy for BRCA-positive breast cancer
BRCA1 and BRCA2 are genes that produce proteins that help fix damaged DNA. Certain changes, called mutations or pathogenic variants, in these genes can disrupt DNA repair and cause cancer to develop.
The following targeted therapy drugs may be used to treat BRCA1- or BRCA2-positive breast cancer:
olaparib
Sources: olaparib
talazoparib
Sources: talazoparib
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Side effects of targeted therapy
The most common side effects of targeted therapy are diarrhea and liver problems. Other side effects may include mouth sores and hair and nail changes. Learn more about the side effects of cancer treatment and steps you can take to manage or prevent them.
Sources: diarrhea · mouth sores · nail changes · side effects of cancer treatment
Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Triple-negative breast cancer (also called TNBC) does not have targets that are typically used to treat other types of breast cancer, but treatment options are available. You and your cancer care team will work together to create a personalized treatment plan, which may include more than one type of treatment. Learn more about Triple-Negative Breast Cancer.
Sources: Triple-Negative Breast Cancer
Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treating stages I–III triple-negative breast cancer
If the cancer is small enough to be removed by surgery, the first treatment for stages I–III (also called stages 1 through 3) TNBC will usually be lumpectomy or mastectomy.
Sources: lumpectomy · mastectomy
Lumpectomy removes the cancer and a small margin of healthy breast tissue around it but not the breast itself. Lumpectomy is sometimes called breast-conserving surgery.
Sources: margin
Mastectomy removes the whole breast that has cancer. Some of the lymph nodes under the arm may also be removed.
Sources: lymph nodes
Learn more about Breast Cancer Surgery.
Sources: Breast Cancer Surgery
For larger tumors, chemotherapy may be given before surgery to shrink the cancer enough to make surgery possible and lessen the amount of breast tissue that needs to be removed during surgery. Additional drugs, such as the immunotherapy drug pembrolizumab, may be given with chemotherapy. Receiving treatment before surgery, called neoadjuvant therapy, may also improve long-term outcomes.
Sources: chemotherapy · immunotherapy · pembrolizumab
Learn about local and systemic treatments and access in-depth information about each type of treatment.
After surgery for TNBC, other treatments may be given to destroy any remaining cancer cells. These include:
more chemotherapy
more of the immunotherapy drug pembrolizumab
the targeted therapy drug olaparib, for those with a BRCA1 or BRCA2 gene mutation and who received chemotherapy both before and after surgery
Sources: targeted therapy · olaparib
radiation therapy, if cancer was found in or near lymph nodes or the tumor margin
Sources: radiation therapy · margin
Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treating metastatic or stage IV (also called stage 4) triple-negative breast cancer
In metastatic (stage IV or stage 4) TNBC, the cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. Treatment for stage IV TNBC is focused on managing the disease and improving quality of life. Treatment options may include:
chemotherapy, which is usually the first treatment
Sources: chemotherapy
targeted therapy, such as olaparib (for those with a BRCA1 or BRCA2 gene mutation) or sacituzumab govitecan
Sources: targeted therapy · olaparib · sacituzumab govitecan
immunotherapy with pembrolizumab
Sources: immunotherapy · pembrolizumab
surgery, such as a mastectomy, to improve symptoms caused by a painful breast tumor or skin lesions
radiation therapy with strontium-89 to relieve pain from cancer that has spread to bones throughout the body
Sources: radiation therapy · strontium-89
radiation to the bones, brain, spinal cord, breast, or chest wall, or areas causing pain or discomfort
Sources: chest wall
Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Treatment for recurrent triple-negative breast cancer
Treatment for TNBC that has recurred (come back) in distant parts of the body may be similar to treatment for stage IV breast cancer. When the cancer recurs locally, such as in the breast or nearby lymph nodes, surgery and radiation therapy may be an option to remove or shrink the tumor.
Learn more about treatments for breast cancer and breast cancer recurrence.
Sources: treatments for breast cancer · breast cancer recurrence
Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.
Source updated: Not stated in this source. Captured 2026-09-09.
Clinical trials
Connect with a cancer information specialist at 1-800-4-CANCER, through live chat, or by email.
Joining a clinical trial may be an option. There are different types of clinical trials for people with breast cancer. For example, a treatment trial tests new treatments or new ways of using existing treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials that are accepting participants. This search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. You can also review a list of NCI-supported Breast Cancer Clinical Trials. Clinical trials supported by other organizations can be found at ClinicalTrials.gov.
Sources: clinical trial search · Breast Cancer Clinical Trials · ClinicalTrials.gov
Learn more about clinical trials at Cancer Clinical Trial Information for Patients and Caregivers.
Sources: Cancer Clinical Trial Information for Patients and Caregivers
Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast...
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordLocally Advanced Breast Cancer, Metastatic Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordEstrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast...
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast...
ClinicalTrials.gov recordBone Metastases
ClinicalTrials.gov recordBone Metastases
ClinicalTrials.gov recordBone Metastases
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordHER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer, Carcinoma of the Breast
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordMetastatic Breast Cancer
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordEstrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast...
ClinicalTrials.gov recordAdvanced Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordMale Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary...
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordHER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
ClinicalTrials.gov recordPrimary Breast Cancer, Her2 Non-overexpressing
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordTriple Negative Breast Cancer
ClinicalTrials.gov recordBreast Cancer, Stage IV Breast Cancer
ClinicalTrials.gov recordBreast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
ClinicalTrials.gov recordBreast Neoplasms, mTor Protein
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordTubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast...
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordTubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast...
ClinicalTrials.gov recordHormone Receptor Positive Breast Cancer
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordMetastatic Breast Cancer
ClinicalTrials.gov recordHER2+ Metastatic Breast Cancer (MBC)
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordMetastatic Breast Cancer
ClinicalTrials.gov recordBreast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
ClinicalTrials.gov recordAdvanced, Metastatic Breast Cancer
ClinicalTrials.gov recordRecurrent Breast Cancer, Stage IV Breast Cancer
ClinicalTrials.gov recordBreast Cancer, HER2 Positive
ClinicalTrials.gov recordBreast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordAdvanced Breast Cancer
ClinicalTrials.gov recordMetastatic Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordEarly Stage Breast Carcinoma
ClinicalTrials.gov recordBreast Neoplasms
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordAdvanced Metastatic Breast Cancer
ClinicalTrials.gov recordEarly Stage HER2+ Breast Cancer
ClinicalTrials.gov recordAdvanced Breast Cancer
ClinicalTrials.gov recordTriple Negative Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordEstrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast...
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordHER-2 Positive Breast Cancer, Metastatic Neoplasm
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordMetastatic Triple Negative Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordHER2 Positive Breast Cancer
ClinicalTrials.gov recordAdvanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial...
ClinicalTrials.gov recordNeutropenia, Breast Cancer
ClinicalTrials.gov recordLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
ClinicalTrials.gov recordTriple Negative Breast Cancer (TNBC)
ClinicalTrials.gov recordBreast Cancer, Neutropenia
ClinicalTrials.gov recordHER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
ClinicalTrials.gov recordNeutropenia, Breast Cancer
ClinicalTrials.gov recordBreast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative...
ClinicalTrials.gov recordTriple Negative Breast Neoplasms
ClinicalTrials.gov recordTriple-Negative Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer, Neutropenia
ClinicalTrials.gov recordEarly Breast Cancer
ClinicalTrials.gov recordTriple Negative Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordHER2-Positive Early Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordEarly Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordMetastatic Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordLocally Advanced (Inoperable) or Metastatic Breast Cancer
ClinicalTrials.gov recordAdvanced or Metastatic Breast Cancer
ClinicalTrials.gov recordHER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
ClinicalTrials.gov recordBreast Cancer; HER2-positive; Metastatic
ClinicalTrials.gov recordER-Positive HER2-Negative Breast Cancer
ClinicalTrials.gov recordBreast Neoplasms, Neoplasm Metastasis
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBreast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
ClinicalTrials.gov recordHER2 Positive Breast Cancer
ClinicalTrials.gov recordBreast Neoplasm, Neoplasm Metastasis
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordTriple Negative Breast Cancer, PD-L1 Positive
ClinicalTrials.gov recordTriple Negative Breast Cancer, PD-L1 Negative
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordAdvanced Breast Cancer
ClinicalTrials.gov recordBreast Cancer
ClinicalTrials.gov recordBone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or...
ClinicalTrials.gov recordBreast Cancer, Vaginal Dryness
ClinicalTrials.gov recordProgressive Metastatic Malignancies
ClinicalTrials.gov recordBrain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma,...
ClinicalTrials.gov recordSexual Dysfunction, Physiological
ClinicalTrials.gov recordBone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or...
ClinicalTrials.gov recordSexual Dysfunction, Breast Cancer Survivors
ClinicalTrials.gov recordAtrophic Vaginitis, Breast Cancer
ClinicalTrials.gov recordPain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer, Breast Cancer, Nervous System Cancer, Chronic Pancreatitis, Stomach Cancer, Renal Cell Carcinoma, Diabetes,...
ClinicalTrials.gov recordMultiple Myeloma, Breast Cancer
ClinicalTrials.gov recordAtrophic Vaginitis
ClinicalTrials.gov recordBreast Cancer, Gynecologic Cancer
ClinicalTrials.gov recordBreast Carcinoma
ClinicalTrials.gov recordLung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
ClinicalTrials.gov recordFebrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Prostate Cancer, Multiple Myeloma, Bladder Cancer, B-cell Lymphoma
ClinicalTrials.gov recordBreast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
ClinicalTrials.gov recordVulvodynia, Dyspareunia, Breast Cancer, Menopause
ClinicalTrials.gov recordLung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer
ClinicalTrials.gov recordBreast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
ClinicalTrials.gov recordEstrogen Levels Among Breast Cancer Patients
ClinicalTrials.gov recordBreast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms
ClinicalTrials.gov recordTumors With CDK4/6 Pathway Activation
ClinicalTrials.gov recordLung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
ClinicalTrials.gov recordVaginal Atrophy
ClinicalTrials.gov recordBreast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception
ClinicalTrials.gov recordBreast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
ClinicalTrials.gov recordMelanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
ClinicalTrials.gov recordAdvanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
ClinicalTrials.gov recordCardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
ClinicalTrials.gov recordVaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
ClinicalTrials.gov recordGynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms,...
ClinicalTrials.gov recordAdvanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Vulva Cancer
ClinicalTrials.gov record1.1 Metastatic Breast Cancer ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
Treatment of Advanced Breast Cancer During Pregnancy
1 INDICATIONS AND USAGE AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment...
1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR ® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after...
1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer.
1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched...
In combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer
1.2 Breast Cancer AVGEMSI in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines...
BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
1.1 Breast Cancer BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
Breast Cancer
CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated...
1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously...
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
1.3 Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2...
1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1...
Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer .
1 INDICATIONS AND USAGE ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] .
ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).
as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.
1.1 HER2-Positive Early Breast Cancer ENHERTU followed by a taxane, trastuzumab, and pertuzumab (THP) is indicated for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer as...
1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II...
1.3 HER2-Low and HER2-Ultralow Metastatic Breast Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or...
( 1.1 ) HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test.
ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting,...
Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting
In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or...
1.2 Advanced Breast Cancer in Postmenopausal Women EXEMESTANE is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
1.1 Adjuvant Treatment of Postmenopausal Women EXEMESTANE is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched...
FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.
• HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
• HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.
Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].
Extended adjuvant treatment of early breast cancer in postmenopausal women who received 5 years of adjuvant tamoxifen
1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.
Postmenopausal women with HR positive early breast cancer
1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.
1 INDICATIONS AND USAGE Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in...
( 1 ) Monotherapy Fulvestrant Injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated...
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.
1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless...
1 INDICATIONS AND USAGE HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
1 INDICATIONS AND USAGE HERCEPTIN HYLECTA is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, indicated in adults for: The treatment of HER2-overexpressing breast cancer.
1.1 Adjuvant Breast Cancer HERCEPTIN HYLECTA is indicated for adjuvant treatment of adults with HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast...
1.2 Metastatic Breast Cancer HERCEPTIN HYLECTA is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast...
1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.
1.1 Adjuvant Breast Cancer Herceptin is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as...
1.2 Metastatic Breast Cancer Herceptin is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer...
1 INDICATIONS AND USAGE HERZUMA is a HER2/neu receptor antagonist indicated in adults for: the treatment of HER2-overexpressing breast cancer.
1.2 Metastatic Breast Cancer HERZUMA is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in...
In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease
1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in...
1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally...
• for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial...
• in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized...
INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine...
1 INDICATIONS AND USAGE INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast...
1 INDICATIONS AND USAGE ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor...
ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2...
IXEMPRA is a microtubule inhibitor indicated for treatment: In combination with capecitabine for patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is...
As a single agent for patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine.
( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
1.2 Early Breast Cancer (EBC) KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based...
1.1 Metastatic Breast Cancer (MBC) KADCYLA ® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
1 INDICATIONS AND USAGE KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received...
1 INDICATIONS AND USAGE KANJINTI is a HER2/neu receptor antagonist indicated in adults for: the treatment of HER2-overexpressing breast cancer.
1.1 Adjuvant Breast Cancer KANJINTI is indicated in adults for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part...
1.2 Metastatic Breast Cancer KANJINTI is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer...
1.18 Triple-Negative Breast Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then...
1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a...
1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III...
( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or...
Treatment of Early/Localized/Operable Breast Cancer During Pregnancy
1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth...
1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated...
1 INDICATIONS AND USAGE MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of...
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one...
Treatment of Metastatic Breast Cancer
1 INDICATIONS AND USAGE NERLYNX is a kinase inhibitor indicated: As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
1.1 Extended Adjuvant Treatment of Early-Stage Breast Cancer NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast...
1.2 Advanced or Metastatic Breast Cancer NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2...
In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.
1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part...
1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in...
1 INDICATIONS AND USAGE Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.
1.1 Adjuvant Breast Cancer Ontruzant is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as...
1.2 Metastatic Breast Cancer Ontruzant is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer...
ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with...
1 INDICATIONS AND USAGE ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic...
1.1 Metastatic Breast Cancer Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within...
1 INDICATIONS AND USAGE Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for...
In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment...
1.1 Metastatic Breast Cancer (MBC) PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or...
1 INDICATIONS AND USAGE PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior...
1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater...
1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of...
1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy...
1 INDICATIONS AND USAGE PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or...
Treatment of Locoregional Recurrent Breast Cancer
1.2 Adjuvant Treatment of Breast Cancer SOLTAMOX is indicated: for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer to reduce the occurrence of contralateral breast cancer in adult...
1.3 Ductal Carcinoma in Situ In adult women with DCIS, following breast surgery and radiation, SOLTAMOX is indicated to reduce the risk of invasive breast cancer [see Boxed Warning and Clinical Studies (14.3) ] .
1 INDICATIONS AND USAGE SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 )
Treatment of stage 0 breast cancer (ductal carcinoma in situ)
Treating stage III (also called stage 3) inflammatory breast cancer
Treatment of stage IV (metastatic) breast cancer
• As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer.
1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer...
Locally advanced or metastatic breast carcinoma that progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy
In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the...
1.1 Adjuvant Breast Cancer TRAZIMERA is indicated in adults for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer
1.2 Metastatic Breast Cancer TRAZIMERA is indicated in adults:
• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal...
1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast...
1.1 HR-positive, HER2-negative locally advanced or metastatic breast cancer TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor...
• in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more...
• in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior...
TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone...
1 INDICATIONS AND USAGE TYKERB ® is indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who...
In combination with letrozole for post-menopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated
VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1) -mutated advanced or...
1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human...
( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or...
in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following...
1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human...
Metastatic breast cancer resistant to paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and further anthracycline therapy is contraindicated
1.2 Breast Cancer XELODA is indicated for the: treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. treatment of patients with...
1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women.
ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or...
DailyMed labelAROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for...
DailyMed labelBEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...
DailyMed label1. INDICATIONS AND USAGE CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial...
DailyMed labelCERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. CERIANNA is a...
DailyMed labelMonotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine...
DailyMed labelConjugated Estrogens Tablets are a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) •...
DailyMed labelDATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer...
DailyMed labelELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] . ELLENCE is an anthracycline topoisomerase...
DailyMed labelENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as...
DailyMed labelEVISTA ® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ) Reduction...
DailyMed labelEXEMESTANE is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for...
DailyMed labelFARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. FARESTON® is an estrogen agonist/antagonist indicated for the...
DailyMed labelMonotherapy FASLODEX is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine...
DailyMed labelFemara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have...
DailyMed labelFulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not...
DailyMed label